ClinicalTrials.gg
RecruitingNCT06058702Updated Nov 18, 2026

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

A Phase 1 interventional study of Delta-9-THC Very Low Dose and Placebo in Schizophrenia and Cannabis Use Disorder, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yale University · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 18, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 57 studies in Schizophrenia by Yale University — 2 open to participants now, 4 under way, none of them phase 3. Schizophrenia · Yale University.

Planned enrollment
2nd of 52
215 · median 34
Started
2024
the only one that year
Phase 1
11 of 57
1 open now
Registered
57th of 57
by date

Among the 57 studies in Schizophrenia by Yale University, this one is the 2nd largest by planned enrollment of the 52 interventional ones that give a count, is the only one that started in 2024, is one of 11 in phase 1, and was the 57th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 57 studies in Schizophrenia by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Schizophrenia by Yale University, or all of them as a file.
02

Study summary

Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher potency of cannabis, the availability of highly potent cannabinoid products, the commercialization of cannabis, and the rising rates of cannabis use, it is critical to understand how genetic factors influence 1) an individual's vulnerability for addiction and psychosis, 2) the response to cannabinoids, 3) the response to novel treatments for CanUD. CanUD is strongly genetically influenced; the investigators published the first CanUD genomewide association study (GWAS) with genomewide-significant results; however, the precise nature of the contribution of genetic factors in the development of CanUD is still not clear. Cannabis exposure has also been linked to a number of psychosis outcomes including schizophrenia (SCZ). SCZ is highly heritable and population-based and genetics studies both support a bidirectional genetic relationship between SCZ and CanUD. However, the precise contribution of genetic factors in the development of psychosis outcomes related to cannabis are not clear.

03

Conditions studied

  • Schizophrenia
  • Cannabis Use Disorder

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Ages 21-70 years old

Exclusion criteria

Exclusion Criteria:

  • Major or unstable medical conditions based on history, the Structured Clinical Interview for , collateral information, physical and laboratory examinations, , and vital signs.
  • Cannabis naïve individuals
  • Positive pregnancy test
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
215 participants (estimated)

Study arms

  • Active comparator
    Delta-9-THC Very Low Dose

    Active delta-9-THC administered intravenously over 20 minutes.

    Drug: Delta-9-THC Very Low Dose

  • Placebo comparator
    Placebo

    Control: small amount of alcohol administered intravenously (quarter teaspoon), with no delta-9-THC, over 20 minutes.

    Drug: Placebo

  • Active comparator
    Delta-9-THC Medium Dose

    Active delta-9-THC administered intravenously over 20 minutes.

    Drug: Delta-9-THC Medium Dose

Interventions

  • DrugDelta-9-THC Very Low Dose

    Active Delta-9-THC administered intravenously over 20 minutes.

  • DrugPlacebo

    Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.

  • DrugDelta-9-THC Medium Dose

    Active Delta-9-THC administered intravenously over 20 minutes.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS)

    The VAS is a scale to document perceived reward. A higher score reflects a positive response.

    Time frame: Measured at baseline, 20 minutes, 45 minutes, 90 minutes, 140 minutes, 165 minutes, 210 minutes, 270 minutes, and 360 minutes after the start of the initial THC/placebo drug infusion.

  2. Positive and Negative Symptom Scale (PANSS)

    The Positive and Negative Syndrome Scale is a 30-item scale to assess both the positive and negative symptom symptoms of schizophrenia. The range total score is 30-210. An improvement in symptoms is reflected by a lower score.

    Time frame: Measured at baseline, 45 minutes, 90 minutes, 165 minutes, 210 minutes, and 360 minutes after the start of the initial THC/placebo drug infusion.

  3. Clinician Administered Dissociative Symptoms Scale (CADSS),

    Perceptual alterations will be measured using scales such as the Clinician Administered Dissociative Symptoms Scale (CADSS), a scale consisting of 19 self-report items and 8 clinician-rated items (0 = not at all, 4 = extremely) that we have shown to be sensitive to THC effects. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.

    Time frame: Measured at baseline, 45 minutes, 90 minutes, 165 minutes, 210 minutes, and 360 minutes after the start of the initial THC/placebo drug infusion.

  4. CogState Battery

    The CogState Battery measures cognition including verbal learning and recall and episodic memory.

    Time frame: Measured at baseline, 45 minutes, and 165 minutes after the start of the initial THC/placebo drug infusion.

07

Study locations

1 of 1 sites recruiting
  • West Haven Veterans Affairs Medical Center
    West Haven, Connecticut 06516, United States
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2028, 51 months after the start.

Of 133 phase 1 interventional studies under Schizophrenia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Sep 28, 2023
StartActual
Sep 16, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Maximum age 60 Years→70 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited-Ages 21-6070 years old
Nov 18, 2026
Contact
Study contact changed: d•••@yale.edu · •••5711→d•••@yale.edu · •••5711. See the current contact
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Eligibility Maximum age 60 Years→70 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited-Ages 21-6070 years old
    Contact Study contact changed: d•••@yale.edu · •••5711→d•••@yale.edu · •••5711. See the current contact
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06058702
Lead sponsor
Yale University
Responsible party
Deepak C. D'Souza (Albert E. Kent Endowed Professor of Psychiatry, Yale University) — Principal investigator
First posted
Sep 28, 2023
Start date
Sep 16, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Erik Zorrilla, PhD
Contact
erik.zorrilla@yale.edu
203-932-5711 ext. 15758
Deepak D'Souza, MD
Contact
deepak.dsouza@yale.edu
203-932-5711 ext. 12594
Deepak D'Souza, MD
principal investigator · Yale University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion